nach oben

Erschienen in:

27.03.2018 | Polyneuropathie | Zertifizierte Fortbildung

Work-up polyneuropathisches Syndrom

Polyneuropathien — was ist diagnostisch sinnvoll?

verfasst von: Prof. Dr. med. Christian Bischoff

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der Begriff Polyneuropathie umfasst eine Vielzahl unterschiedlicher Erkrankungen und Erscheinungsformen. Diagnostik und ätiologische Zuordnung sind von enormer Bedeutung bei diesem Krankheitsbild mit hoher Prävalenz. Am Anfang stehen die Anamneseerhebung sowie die klinische Untersuchung. Zusatzuntersuchungen dienen dazu, eine weitere Einordnung des polyneuropathischen Syndroms vorzunehmen mit dem Ziel, eine Ursache zu finden.

Hanewinckel R, Drenthen J, van Oijen M, Hofman A, van Doorn PA, Ikram MA. Prevalence of polyneuropathy in the general middle-aged and elderly population. Neurology 2016; 87(18):1892–8CrossRefPubMed

Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol 2016; 31:5–20CrossRefPubMed

Zis P, Sarrigiannis PG, Rao DG, Hewamadduma C, Hadjivassiliou M. Chronic idiopathic axonal polyneuropathy: a systematic review. J. Neurol 2016; 263:1903–10CrossRefPubMed

Morrison B, Chaudry V. Medication, toxic and vitamin-related neuropathy. Continuum 2012; 18:139–60PubMed

Windebank AJ, Grisold W. Chemotherapy induced neuropathy. J Peripher Nerv Syst 2008; 13:27–46CrossRefPubMed

Kastenbauer T, Sauseng S, Brath H, Abrahamian H, Irsigler K. The value of the Rydel-Seiffert tuning fork as a predictor of diabetic polyneuropathy compared with a neurothesiometer. Diabet Med 2004; 21:563–7CrossRefPubMed

England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64(2):199–207CrossRefPubMed

Watson JC, Dyck PBJ. Peripheral neuropathy: A practical approach to diagnosis and symptom management. Mayo Clin Proc 2015; 90:940–51CrossRefPubMed

Devigili G et al. The diagnostic criteria for small fiber neuropathy: from symptoms to neuropathology. Brain 2008; 131:1912–25CrossRefPubMedPubMedCentral

10.

Bromberg M. An electrodiagnostic approach to the evaluation of peripheral neuropathies. Phys Med Rehabil Clin N Am 2013; 24:153–68CrossRefPubMed

11.

Bischoff C. Polyneuropathien. in: Bischoff C, Dengler R, Hopf HC (ed). EMG NLG. Thieme, Stuttgart 2014; p. 154–9

12.

Schulte-Mattler W. Conduction Velocity Distribution. In: Kimura J, editor. Neurophysiology of Peripheral Nerve Diseases. Amsterdam: Elsevier; 2006. p. 405–19

13.

Backonja MM, Walk D, Edwards RR, Sehgal N, Moeller-Bertram T, Wasan A, Irving G, Argoff C, Wallace M. Quantitative sensory testing in measurement of neuropathic pain phenomena and other sensory abnormalities. Clin J Pain 2009; 25:641–7CrossRefPubMed

14.

Thaisetthawatkul P, Fernandes Filho JA, Herrmann DN. Contribution of QSART to the diagnosis of small fiber neuropathy. Muscle Nerve 2013; 48:883–8CrossRefPubMed

15.

Stoll G, Bendszus M, Perez J, Pham M. Magnetic resonance imaging oft her peripheral nervous system. J Neurol 2009; 256:1043–51CrossRefPubMed

16.

Gasparotti R, Padua L, Briani C, Lauria G. New technologies for the assessment of neuropathies. Nature Reviews Neurology. 2017; 13:203–16CrossRefPubMed

17.

Gasparotti et al. Neuroimaging in the diagnosis of atypical polyradiculopolyneuropathies: report of three cases and review of the literature. J Neurol 262:1714–23

18.

Van den Bergh PY et al. European Federation of Neurological Science/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating neuropathy: report of a joint task force of the European Federation of Neurological Science and the Peripheral Nerve Society. Eur J Neurol 2010; 17:356–63CrossRefPubMed

19.

Ellegala DB et al. Characterization of genetically defined types of Charcot-Marie-Tooth neuropathies by using magnetic resonance imaging. J Neurosurg 2005; 102:242–5CrossRefPubMed

20.

Zaidman CM, Harms MB, Pestronk A. Ultrasound of inherited versus acquired demyelinating neuropathies. J Neurol 2013; 260:3115–21CrossRefPubMedPubMedCentral

21.

Grimm A et al. Ultrasound pattern sum score, homogeneity score and regional nerve enlargement index for the differentiation of demyelinating inflammatory and hereditary neuropathies. Clin Neurophysiol 2016; 127:2618–24CrossRefPubMed

22.

Dyck PJ, Katz, KM, Karres, JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43:817–24CrossRefPubMed

23.

Bulton AJ, Vinik AL, Arezzo J et al. Diabetic neuropathies a statement by the American Diabetes Association. Diabetes Care 2005; 28:956–62CrossRef

24.

Hoffman-Snyder C, Smith BE, Ross MA, Hernandez J, Bosch EP. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol 2006; 63(8):1075–9CrossRefPubMed

25.

Hanewinckel R, Drenthen J, Ligthart S, Dehghan A, Franco OH, Hofman A et al. Metabolic syndrome is related to polyneuropathy and impaired peripheral nerve function: a prospective population-based cohort study. J Neurol Neurosurg Psychiatr. 2016; 87(12):1336–42CrossRef

26.

Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001; 24:1448–53CrossRefPubMed

27.

Summer CJ, Sheth S, Griffin JW, Cornblath DR, Podydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60:108–11CrossRef

28.

Saperstein DS, Wolfe GJ, Gronseth GS et al. Challenges in the identification of cobalamin-deficiency polyneuropathy. Arch Neurol 2003; 60:1296–301CrossRefPubMed

29.

Smith AG, Singleton JR. The diagnostic yield of a standardized approach to idiopathic sensory-predominant polyneuropathy. Arch Intern Med. 2004; 164:1296–1301

30.

Callaghan BC, Price RS, Feldman EL. Diagnostic and therapeutic advances: distal symmetric polyneuropathy. JAMA 2015; 314:2172–81CrossRefPubMedPubMedCentral

31.

Kelly JJ, Kyle RA, O’Brien PC, Dyck PJ. Prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981; 31:1480–3CrossRefPubMed

32.

Kahn SN, Bira M. Sensitivity of immunofixation electrophoresis for detecting IgM paraproteins in serum. Clin Chem 1988; 34:1633–5PubMed

33.

Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn PJ. Distal acquired demyelinating symmetric neuropathy. Neurology 2005; 615–20

34.

Chaudry HM, Mauermann ML, Rajkumas SV. Monoclonal gammopathy-associated peripheral neuropathy: Diagnosis and management. Mayo Clin Proc 2017; 92:838–50CrossRef

35.

Braathen GJ, Sand JC, Lobato A, Hoyer H, Russel MB. Genetic epidemiology of Charcot-Marie-Tooth in the general population. Eur J Neurol 2011; 18:39–48CrossRefPubMed

36.

England JD, Groseth GS, Franklin G et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory genetic testing. Neurology 2009; 72:185–92CrossRefPubMed

37.

Gallagher G, Rabquer A, Kerber K, Cabalek B, Callaghan B. Value of thyroid and rheumatologic studies in the evaluation of peripheral neuropathy. Neurology Clinical practice 2013; 3:90–8CrossRefPubMedPubMedCentral

38.

Van den Bergh PYK, Haddenb RDM, Bouchec P, Cornblathd DR, Hahne A, Illaf I, Koskig CL, J. Légerh JM, Nobile-Orazioi E, Pollardj J, Sommerk C, van Doornl PA, van Schaik IN. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision Members of the Task Force. Eur J Neurol 2010; 17:356–63CrossRefPubMed

39.

Luria G. et al. European Federation of Neurological Science/Peripheral Nerve Society guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. J Periph Nerv Syst 2010; 15:79–92CrossRef

40.

Sachedina S, Toth C. Progression in idiopathic, diabetic, paraproteinemic, alcoholic and B12 deficiency neuropathy. J Periph Nerv Syst 2013; 18:247–55CrossRef

41.

Wolfe GI, Baker NS, Amato AA, Jackson CE, Nations SP, Saperstein DS et al. Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics. Arch Neurol 1999; 56:540–7CrossRefPubMed

42.

Notermans NC, Wokke HJ, van der Graaf Y, Franssen H, van Dijk GW, Jennekens FG. Chronic idiopathic axonal neuropathy: a five year follow-up. J Neurol Neurosurg Psychiat 1994; 57:1525–7CrossRefPubMed

43.

Euerlings M, van den Berg LH, Wokke JH, Franssen H, Vrancken AF, Notermans NC. Increase of sural nerve T cells in progressive axonal neuropathy and monoclonal gammopathy. Neurology 2003; 61:707–9CrossRef

44.

Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014 Sep 19;(9):CD002063. doi: 10.1002/14651858.CD002063.pub6.

45.

Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017 Jan 13;1:CD010369. doi: 10.1002/14651858.CD010369.pub2

46.

Finsterer J, Wanschitz J, Quasthoff S, Iglseder S, Löscher W, Grisold W. Causally treatable, hereditary neuropathies in Fabry’s disease, transthyretin-related familial amyloidosis, and Pompe’s disease. Acta Neurol Scand 2017; 136(6):558–69CrossRefPubMed

47.

Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79:785–92CrossRefPubMedPubMedCentral

48.

Berk JL, Suhr OB, Obici L et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310:2658–67CrossRefPubMedPubMedCentral

49.

Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2016 Oct 4;10:CD002827

50.

Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane. Database Syst Rev 2012; 6:CD007543PubMedCentral

51.

Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393–403CrossRefPubMed

52.

Dworkin RH, O’Connor AB, Audette J et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85(suppl):S3–S14CrossRefPubMedPubMedCentral

53.

Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17:1113–e88CrossRefPubMed

54.

Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012; 7:CD008943

Titel: Work-up polyneuropathisches Syndrom
Polyneuropathien — was ist diagnostisch sinnvoll?
verfasst von: Prof. Dr. med. Christian Bischoff
Publikationsdatum: 27.03.2018
Verlag: Springer Medizin
Schlagwörter: Polyneuropathie
Small-Fiber-Neuropathie
Erschienen in: DNP – Die Neurologie & Psychiatrie / Ausgabe 2/2018
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI: https://doi.org/10.1007/s15202-018-1879-8

Neu in den Fachgebieten Neurologie und Psychiatrie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Polyneuropathien — was ist diagnostisch sinnvoll?

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Delir kann Demenz begünstigen

Manche Gestagene können das Risiko für Meningeome erhöhen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Schlaganfall: Sekundärprävention macht deutliche Fortschritte

Körpergröße bei Kindern und Schlaganfallrisiko im Erwachsenenalter – Nachteil für die Kleinen?

Höheres Herzinfarkt- und Schlaganfallrisiko durch Migräne

Epilepsiekranke werden noch immer zu spät operiert

NOAK-Antagonist Idarucizumab in der klinischen Praxis

RNA-Therapeutikum effektiv bei hereditärer Amyloidose

Neu in den Fachgebieten Neurologie und Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Delir kann Demenz begünstigen

Manche Gestagene können das Risiko für Meningeome erhöhen